Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
It’s time to measure outcomes
Lucid launch their new metrics platform
Lucid’s new branding is magic
Lucid Group launch their new branding in this month's PME magazine.
A summer meeting full of magical moments
In their day-to-day, everybody at Lucid Group strives to develop outstanding medical education programmes to improve patient outcomes. Over the summer, however, they like to take some time to turn...
Sir Henry presents Queen’s Award for Enterprise to Lucid Group
On 13 July, Lord Lieutenant Sir Henry presented Lucid Group with the Queen’s Award for Enterprise in International Trade. This award recognises UK-based businesses that have achieved outstanding growth overseas...
Lucid Group’s winning formula is recognised at Communiqué 2017
Lucid Group’s commitment to improving patient outcomes across the globe was recognised at the 2017 Communiqué Awards in London last night. The agency won the awards for Excellence in Communications...
Lucid Partners grows its medical writing team
The past year has been the most successful for Lucid Group yet. They have celebrated their 10th year of business, launched their new Strategic Consultancy, won a Queen’s Award for...
Using insights to effect behaviour change
The days when medical communication simply aimed to raise awareness of clinical challenges are well and truly over. In recent years, we have seen a clear shift towards changing physicians’...
All five of Lucid’s entries reach the shortlist for Communiqué 2017
Lucid Group is thrilled to learn that all its entries for the 2017 Communiqué Awards have been shortlisted as finalists! The categories include: Communications Consultancy of the Year Lucid Group Excellence in Communications via...
Your career starts here
When working in medical communications, one of the most common questions we get asked is “What is it that you actually do?” Many students and graduates are unaware of medical...
Are you suffering from templatitis?
At times, it feels like procedures are designed to frustrate, and templates often hinder rather than help. Especially in strategic planning, where a certain degree of creativity and innovation is...